

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Appointment of Joint Broker

LONDON and PHILADELPHIA - February 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Panmure Liberum Limited ("Panmure Liberum") as its joint broker with immediate effect. Panmure Liberum will work alongside Peel Hunt, the Company's Nominated Adviser and existing corporate broker.

-Ends-

For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications
Director

avacta.com

Peel Hunt (Nomad and Joint Broker)

James Steel / Chris Golden / Patrick Birkholm

www.peelhunt.com

Panmure Liberum (Joint Broker)

Emma Earl, Will Goode, Mark Rogers
David Cox (Healthcare Specialist Sales)

www.panmureliberum.com

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie
Cuthbert

avacta@consilium-comms.com

Investor and Communications Contact

Renee Leck
THRUST Strategic Communications

www.thruststrategiccommunications.com

Media Contact

Carly Scaduto
Carly Scaduto Consulting

Carly@carlyscadutoconsulting.com

About Avacta - <http://avacta.com/>

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION[®] platform. pre|CISION[®] is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION[®] peptide drug conjugates (PDC) or Affimer[®] drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPSSWESDEISEFE